Once-weekly Byetta shows superiorty over oral antidiabetics in Phase III
03 April 2009
Malini Guha
Please Login to read the full article.
03 April 2009
Malini Guha
Malini.guha@informa.com
Lilly/
Amylin's once-weekly version of the twice-daily injectable diabetes drug Byetta (exenatide), a GLP-1 analogue, has been shown in a Phase III trial to provide improved glucose control and weight loss than two oral antidiabetics, Merck & Co's DPP-4 inhibitor Januvia (sitagliptin) and Takeda's...
Please Login to read the full article.
RELATED CONTENT
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
